Your browser doesn't support javascript.
loading
A Comprehensive Review of Lemborexant to Treat Insomnia.
Fuller, Mitchell C; Carlson, Samuel F; Grant, Chris; Berry, Vince; Ivancich, Marko; Cornett, Elyse M; Kaye, Adam M; Viswanath, Omar; Urits, Ivan; Shekoohi, Sahar; Kaye, Alan D.
Afiliación
  • Fuller MC; Fuller, MD, Dartmouth School of Medicine, Department of Anesthesiology, Hanover, NH.
  • Carlson SF; Carlson, MD, University of Iowa, Department of Surgery, Iowa City, IA.
  • Grant C; Grant, MD, University of California, Irvine, Department of Internal Medicine, Irvine, CA.
  • Berry V; Berry, MD, University of Chicago, Department of Anesthesiology, Chicago, IL.
  • Ivancich M; Ivancich, MD, Cape Fear Valley Health, Department of Psychiatry, Fayetteville, NC.
  • Cornett EM; Cornett, PhD, Louisiana State University Shreveport, Department of Anesthesiology, Shreveport LA.
  • Kaye AM; Kaye, Pharm D, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Department of Pharmacy Practice, Stockton, CA.
  • Viswanath O; Viswanath, MD, Louisiana State University Shreveport, Department of Anesthesiology, Shreveport LA; University of Arizona College of Medicine-Phoenix, Department of Anesthesiology, Phoenix, AZ; Valley Anesthesiology and Pain Consultants-Envision Physician Services, Phoenix, AZ; Creighton University S
  • Urits I; Urits, MD, Louisiana State University Shreveport, Department of Anesthesiology, Shreveport LA.
  • Shekoohi S; Shekoohi, PhD, Louisiana State University Shreveport, Department of Anesthesiology, Shreveport LA.
  • Kaye AD; Kaye, MD, PhD, Louisiana State University Shreveport, Department of Anesthesiology, Shreveport LA.
Psychopharmacol Bull ; 54(1): 43-64, 2024 Mar 04.
Article en En | MEDLINE | ID: mdl-38449475
ABSTRACT
Purpose of Review This is a comprehensive review of the literature regarding Lemborexant for the treatment of insomnia. It covers the background and management of insomnia and then reviews the body of existing evidence evaluating the use of Lemborexant for this purpose. Recent

Findings:

Insomnia leads to significant decreased in quality of life and economic burden due to decreased workplace performance and increased health care costs. Insomnia manifests as a single common pathway of hyperarousal due to a highly complex network of interactions between activation of the sympathetic system and the endocrine system. Lemborexant is a dual orexin 1/2 antagonist that blocks cortical arousal and promotes sleep state transition. Lemborexant was approved by the FDA in 2019 for use in insomnia. It belongs to a class of orexin neuropeptide inhibitors that is growing in popular clinical application.

Summary:

Insomnia is a crippling disorder of the sleep wake cycle that drives significant morbidity and mortality in the United States. It carries a high societal and economic toll due to direct and indirect effects to the healthcare system. Lemborexant is a new addition to the orexin antagonist class of drugs that already includes Almorexant and Suvorexant that has superior pharmacokinetic properties. While Lemborexant does have a mild side effect profile, its clinical safety and efficacy make it a promising insomnia drug of the future.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Pirimidinas / Trastornos del Inicio y del Mantenimiento del Sueño Límite: Humans Idioma: En Revista: Psychopharmacol Bull Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Pirimidinas / Trastornos del Inicio y del Mantenimiento del Sueño Límite: Humans Idioma: En Revista: Psychopharmacol Bull Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos